This discussion-based activity will inform and guide on the latest practice-changing evidence for adjuvant and neoadjuvant approaches in the treatment of early-stage non-small cell lung cancer (NSCLC).
Launch Date: September 12, 2022
Expiration Date: August 31, 2023
This program is intended for clinicians who treat/manage patients with non-small cell lung cancer. This includes community and institution based medical oncologists, surgical oncologists, pulmonologists, and other oncology healthcare providers (nurse practitioners. physician assistants and nurses).
Upon completion of this enduring material, participants should be better able to:
In compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, it is the policy for all accreditors of this accredited continuing education activity as named above to ensure accuracy, balance, objectivity, independence, and scientific rigor in all their educational activities, and to commit to protecting learners from promotion, marketing, and commercial bias. All faculty, planners and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. This enduring material may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of the accredited providers and Practice Point Communications.
The accredited providers have mitigated and are disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:
PLANNING COMMITTEE DISCLOSURE INFORMATION
The below planning committee members have nothing to disclose:
UNMC: Omar Abughanimeh, MBBS; Valeta Creason-Wahl; Heidi Keeler, PhD, RN; Renee Paulin, MSN, RN, CWOCN; Brenda Ram, CMP, CHCP
PPC: Nirupama Mulherkar, Martin Stevens, Jill Valone
Julie R. Brahmer, MD, MSc
Grant Research Funding: AstraZeneca, Bristol-Myers Squibb
Advisory Board: Janssen
Jamie Chaft, MD
Consultant: AstraZeneca, Bristol-Myers Squibb, Flame Biosciences, Genentech, Guardant Health, Janssen, Merck, Novartis, Regeneron
Stephen Liu, MD
Consultant: Amgen, AstraZeneca, Bayer, Beigene, Blueprint, Boehringer Ingelheim, Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech, Gilead Sciences, Guardant Health, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics
Grant Research Funding: Bayer, Blueprint, Bristol-Myers Squibb, Elevation Oncology, Genentech, Gilead Sciences, Lilly, Merck, Nuvalent, Pfizer, Rain, RAPT, Turning Point Therapeutics
The University of Nebraska Medical Center and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The University of Nebraska Medical Center and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME and ANCC.
The University of Nebraska Medical Center and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:
The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.
Supported by an independent educational grant from Merck Sharp & Dohme, LLC.